GRANTS

147 RESULTS

To submit a grant posting, please fill out our web form or download the form so that you can email us at grants@alzforum.org. List the sponsor name, amount, due date, and contact information. This is a free service.

Please Note: We remove grant postings after 6 months. If you would like your listing to be posted longer or taken down sooner, please contact us at grants@alzforum.org.

BRAIN Initiative: Development and Validation of Novel Tools to Analyze Cell-Specific and Circuit-Specific Processes in the Brain (R01)

Sponsor: National Institute of Mental Health, National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and Other Communication Disorders, National Institute of Neurological Disorders and Stroke

SBIR/STTR Commercialization Readiness Pilot (CRP) Program: Technical Assistance (SB1)

Sponsor: National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism. National Institute of Biomedical Imaging and Bioengineering, National Institute of Dental and Craniofacial Research, National Institute of Environmental Health Sciences

Due Date: Multiple dates; see announcement

SBIR/STTR Commercialization Readiness Pilot (CRP) Program: Technical Assistance and Late Stage Development (SB1)

Sponsor: National Institute of Neurological Disorders and Stroke, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health

Due Date: Multiple dates; see announcement

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R3

Sponsor: National Institute of Neurological Disorders and Stroke, National Institute on Drug Abuse

Award: NINDS intends to commit up to $750,000 per year to fund up to 3 new awards per year in fiscal years 2016, 2017, and 2018 for a potential total of 9 new awards over the three years.

Due Date: October 18, 2016; February 21, 2017; June 21, 2017; October 18, 2017 , by 5 p.m. local time of applicant organization.

Novel Genomic Technology Development (R01)

Sponsor: National Human Genome Research Institute

Award: An applicant may request direct costs of up to $700,000 per year.

Due Date: October 31, 2016; October 31, 2017, by 5 p.m. local time of applicant organization.

Novel Genomic Technology Development (R21)

Sponsor: National Human Genome Research Institute

Award: An applicant may request direct costs of up to $200,000 per year and no more than $400,000 for the entire budget period.

Due Date: October 31, 2016; October 31, 2017, by 5 p.m. local time of applicant organization.

Novel Genomic Technology Development (R43/R44)

Sponsor: National Human Genome Research Institute

Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1 million for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1.5 million for Phase II). NIH has received a waiver from SBA, as authorized by the statute, to exceed the hard cap for specific topics.

Due Date: October 31, 2016; October 31, 2017, by 5 p.m. local time of applicant organization.

Novel Genomic Technology Development Direct to Phase II SBIR (R44)

Sponsor: National Human Genome Research Institute

Award: Total funding support (direct costs, indirect costs, fee) normally may not exceed $1 million for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50 percent ($1.5 million for Phase II). NIH has received a waiver from SBA, as authorized by the statute, to exceed the hard cap for specific topics.

Due Date: October 31, 2016, by 5 p.m. local time of applicant organization.

SBIR Technology Transfer (R43/R44)

Sponsor: National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences, National Cancer Institute, National Eye Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, National Institute of Dental and Craniofacial Research, National Institute of Nursing Research

Award: Total funding support normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification, Congress will allow awards to exceed these amounts by up to 50 percent ($225,000 for Phase I and $1,500,000 for Phase II). NIH can apply for a waiver from SBA to issue an award exceeding $225,000 for Phase I or $1,500,000 for Phase II, if this cap will interfere with NIH‘s ability to meet its mission.

Due Date: Multiple dates, see announcement.

Current Filters

No filters selected

Filter By